SCAP and prostate cancer: Guo et al. (2019) knocked down SCAP, which inhibited the growth and adipogenic differentiation of liver cancer cells. Additionally, in prostate cancer, SREBP-2 induces the proliferation, invasion and migration of prostate cancer cells. Overexpression of SREBP-2 increases the number of prostate cancer stem cells. Genetic silencing of SREBP-2 inhibits the proliferation and metastasis of prostate cancer cells (Li et al., 2016).